Siemens bets on spin-offs amid investor jitters and tariffs

Siemens’ strategic portfolio reshaping is fundamentally driven by a desire to sharpen its focus on innovation and future growth markets, as evidenced by the planned 2027 spin-off of Siemens Healthineers. This move aligns with the company’s broader digitalization strategy, which leverages strong performance metrics such as a record order intake of 27.9 billion euros and 8% revenue growth, particularly in digital infrastructure and industrial applications. By concentrating on specialized technology markets like AI computing, Siemens aims to capitalize on emerging high-demand sectors, exemplified by its development of a specialized transformer for AI data centers.

Parallel to Siemens’ focus on innovation, Siemens Energy is undertaking a strategic divestment of its industrial division to streamline operations and concentrate on the expanding utility sector. The planned spin-off of the Transformation of Industry business unit, which manufactures steam turbines, compressors, and generators, is designed to grant the new entity greater entrepreneurial flexibility and growth potential through external investment and capital market opportunities. Despite selling a majority stake, Siemens Energy’s retention of a significant minority share underscores a long-term commitment to supporting the division’s development, particularly as it advances industrial energy solutions that enhance production efficiency and reduce carbon emissions.

Siemens Healthineers has been grappling with a confluence of operational and market challenges that have significantly dampened its growth trajectory and investor confidence. The imposition of a 10% US tariff on European imports has placed the company in a strategic bind, forcing it to choose between raising prices—risking market share loss in North America—or localizing production, which demands substantial time and capital investment, both scenarios eroding margins. Concurrently, the diagnostics division faces intense competitive pressures in China exacerbated by procurement policy shifts and costly transitions to new lab platforms, prompting management to lower organic revenue growth forecasts from an initial 4.5%-5.0% down to 3.5%-4.0%. These operational headwinds have contributed to a marked share price decline of over 22% year-to-date, reflecting investor wariness amid ongoing uncertainty around the spin-off execution and the future of the diagnostics unit.

Investor sentiment remains cautious and somewhat constrained by structural uncertainties surrounding Siemens Healthineers’ strategic roadmap. The planned spin-off of a 30% stake remains in limbo with no shareholder votes scheduled, leaving the stock rangebound and vulnerable to technical pressures, trading just above its 50-day moving average but well below its 200-day average. Meanwhile, the diagnostics division’s potential divestment, complicated by weak Chinese market conditions and adverse currency effects, adds another layer of complexity, with CFO Jochen Schmitz indicating that preparing the unit for sale could take up to 24 months. This protracted timeline risks prolonging capital consumption from an underperforming segment, though a faster divestment process could materially improve the stock’s outlook.

Despite a modest technical rebound of about 12% from May lows, Siemens Healthineers’ shares remain significantly down year-to-date and over the past twelve months, underscoring persistent investor caution amid mixed operational signals. While tariff reimbursements have temporarily buoyed adjusted earnings per share forecasts to €2.35–€2.45, this improvement masks underlying weakness, particularly in the large imaging segment which continues to lag. The upcoming leadership change in the Americas, with João Seabra set to succeed John Kowal as President and Head of Americas, may offer a fresh impetus in a critical region, but the market is holding its breath for clearer signs of structural progress before embracing a more optimistic view.

Despite Siemens' record financial performance and a 19% year-to-date stock gain under CEO Roland Busch's leadership, internal governance tensions persist, notably voiced by Tobias Bäumler, chairman of the group works council, who criticized past divestitures like Siemens Healthineers and Siemens Energy as strategic missteps. This dissent underscores a demand for greater workforce transparency amid ongoing restructuring, even as Siemens moves to reduce managerial overlap by cutting supervisory board seats held by its executives in spun-off entities, signaling a deliberate effort to clarify corporate governance and reassure investors.

The resolution of tax uncertainties surrounding the Siemens Healthineers spin-off, coupled with leadership’s cautious yet committed stance—evidenced by CFO Veronika Bienert’s communication and nearly 2.8 million shares repurchased—reflects a governance approach balancing fiscal clarity with shareholder value support. However, tempered growth forecasts and a focus on cost discipline amid slowing revenue growth have led to mixed investor sentiment, with shares down 13% year-to-date and volatility hovering at 32%, illustrating market ambivalence between margin-focused confidence and growth-oriented skepticism.

Investor confidence remains cautious as Siemens Healthineers navigates a complex restructuring timeline, with CFO Jochen Schmitz indicating up to 24 months may be required to prepare the diagnostics unit for sale, a duration that risks extending capital consumption and dampening near-term value creation. Although adjusted EPS forecasts have improved to €2.35–€2.45, largely driven by tariff reimbursements rather than organic momentum, and recent leadership changes such as João Seabra’s appointment as President and Head of Americas could inject fresh energy, market analysts like Deutsche Bank maintain a 'Hold' rating, reflecting limited upside amid ongoing structural uncertainties.

Siemens is advancing its strategic portfolio reshaping with the highly anticipated spin-off of Siemens Healthineers slated for 2027, a move underscored by the recent resolution of critical tax uncertainties with German authorities that clears a major regulatory hurdle. This milestone aligns with Siemens’ broader digitalization strategy, exemplified by product innovations such as the specialized transformer for AI data centers, positioning the company to capitalize on emerging technology trends while enhancing operational focus.

Despite a tempered growth outlook for Siemens Healthineers—now projecting 3.5 to 4.0 percent revenue growth down from earlier estimates—the company has simultaneously raised its adjusted earnings-per-share forecast, reflecting disciplined cost management amid cooling momentum. The upcoming pivotal FDA meeting on October 1 for the RAD101 imaging agent, which benefits from a Fast Track designation, represents a critical catalyst that could materially influence Healthineers’ growth trajectory and investor sentiment as it approaches spin-off execution.

Siemens Healthineers’ stock performance remains volatile despite proactive share buybacks totaling nearly 2.8 million shares between June and mid-August, with volatility at 32 percent and the price lingering just below its 200-day moving average. This market behavior highlights investor caution as the company navigates the complex spin-off process and awaits key product development milestones, underscoring the delicate balance between management confidence and market skepticism.

Parallel to the Healthineers spin-off, Siemens Energy is preparing to separate its ‘Transformation of Industry’ business into an independent entity, aiming to unlock entrepreneurial agility and growth potential through external investment or capital market transactions. While Siemens Energy plans to deconsolidate this unit, it will maintain a significant minority stake, signaling a strategic commitment to support the new company’s development in industrial energy solutions and reflecting a broader trend within Siemens to streamline operations and foster focused growth platforms.